Haleon Pakistan Limited, formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited, has announced an investment of $10 million to accelerate the production of commonly known tablets Panadol and CaC 1000 Plus at its manufacturing facility in Jamshoro, Sindh.
The company said in a stock filing that the investment was aimed at bringing the latest manufacturing technology to Pakistan and enhancing the production capacity to 8 billion tablets. This will help the company to ensure smooth supplies of Pakistan’s largest pharmaceutical over-the-counter medicine to consumers and patients in need.
The board of directors of Haleon Pakistan approved the investment and associated financing for the production of the Panadol base portfolio, including Panadol 500mg and Panadol Extra tablets. This is in addition to the investment of $2 million being spent on enhancing the manufacturing facility of the flagship brand CaC 1000 Plus to cater to local needs and export opportunities.
Haleon Pakistan Limited was incorporated in Pakistan as a publicly listed company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on 31st March 2015. It is a subsidiary of Haleon Netherlands B.V and is ultimately owned by Haleon plc.
The company is principally engaged in the manufacturing, marketing and sale of consumer healthcare and over the counter health products.
Haleon Pakistan reported a 13 percent increase in its profit after tax for the first half of 2023, reaching Rs313 million, compared to Rs277.28 million in the same period last year.